Skip to main content

Table 1 Baseline demographic and clinical characteristics of the study patients

From: Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials

Variable

Iron Sucrose (N = 100)

Ferric Carboxymaltose (N = 100)

Age – year

27·32 ± 4·15

30·41 ± 7·99

Height – cm

158 ± 6·54

158·29 ± 7·11

Body weight – kg

59·07 ± 6·91

59·36 ± 6·23

Body mass indexa

23·68 ± 2·56

23·80 ± 3·10

Blood Pressure – mm Hg

Systolic

111·86 ± 6·68

110·85 ± 7·10

Diastolic

71·71 ± 5·39

71·57 ± 5·19

Pulse – beats/min

80·49 ± 4·57

81·43 ± 5·46

Medical Condition –– no.

 Pregnancy

  First Trimester

  Second Trimester

8

9

  Third Trimester

39

39

 Postpartum

20

19

 Menorrhagiab

20

18

 Fibroid Uterus + Heavy Bleedingc

6

7

 Ovarian cyst

7

7

 Ligation

1

Co-morbidities –– no.

 Diabetes

2

3

 Thyroid Disorder

6

8

 Gastrointestinal Disorder

9

13

 Urinary tract infections

7

9

 Vitamin and Mineral Deficiencies

47

45

 Other

12

11

Concomitant Treatment –– no.

 Insulin

2

3

 Drugs for Thyroid Disorder

6

8

 Antacids/ PPIs

11

11

 Antibiotics

11

18

 Multi-vitamin and Mineral supplements.

49

48

 Other

9

10

  1. ± Plus-minus values are of standard deviation
  2. aThe body mass index is the weight in kilograms divided by the height in meters
  3. bBleeding have been continuous for more than 7 days with heavy clots, disrupted cycle associated with pain. More than 2 pads or tampons every 2 h, doubling of pads or tampons to manage menstrual flow
  4. cProlonged periods (>12 days); hot flushes; disrupted sleep pattern; pain in joints; More than 2 pads or tampons every 1 h, doubling of pads or tampons to manage menstrual flow